Metabolism - Clinical and Experimental
Volume 46, Issue 2 , Pages 173-178, February 1997

Insulin sensitivity, glucose effectiveness, and β-cell function in obese males with essential hypertension: Investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril)

  • José Cabezas-Cerrato

      Affiliations

    • Corresponding Author InformationAddress reprint requests to José Cabezas-Cerrato, MD, Servicio de Endocrinologia y Nutrición, Complejo Hospitalario Universitario de Santiago (Hospital Xeral), r/Galeras, s/n, 15705 Santiago de Compostela, Spain.
    • Endocrinology and Nutrition Service, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • Department of Medicine, University of Santiago, Santiago de Compostela, Spain
  • ,
  • Daniel A. Garcia-Estevez

      Affiliations

    • Endocrinology and Nutrition Service, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • Department of Medicine, University of Santiago, Santiago de Compostela, Spain
  • ,
  • David Araújo

      Affiliations

    • Endocrinology and Nutrition Service, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • Department of Medicine, University of Santiago, Santiago de Compostela, Spain
  • ,
  • Manuel Iglesias

      Affiliations

    • Endocrinology and Nutrition Service, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • Department of Medicine, University of Santiago, Santiago de Compostela, Spain

Received 28 February 1996; accepted 11 September 1996.

Abstract 

It has been suggested that hyperinsulinemia secondary to insulin resistance may be a pathogenetic factor common to obesity, non-insulin-dependent diabetes mellitus (NIDDM), and hypertension. Furthermore, β-blockers and thiazide diuretics have been shown to be capable of increasing insulin resistance and thus of inducing NIDDM in predisposed individuals. We used the minimal model approach (MMA) to glucose metabolism and insulin kinetics to compare peripheral insulin sensitivity and β-cell function in hypertensive and normotensive obese men. The hypertensive group consisted of 37 obese men with mild to moderate hypertension; following a drug-free period of 4 weeks, 20 of these subjects received diltiazem and 17 quinapril over the 12-week study period. The normotensive (control) group contained 17 obese men without microalbuminuria, dyslipidemia, or a family history of essential hypertension or NIDDM. Before and at the end of the 12-week study period, subjects underwent frequently sampled intravenous glucose tolerance (FSIGT) tests. The results were used to estimate an insulin sensitivity index (S1), a glucose effectiveness index (SG), and β-cell sensitivity to glucose indices during first- and second-phase insulin secretion (Φ1 and Φ2) using the minimal models of glucose metabolism and insulin kinetics. No significant differences in Sl or SG were detected between the hypertensive and control groups. Twelve weeks' treatment with diltiazem led to a slight but significant increase in Φ1; however, neither diltiazem nor quinapril had significant effects on Sl or SG. We conclude that men with obesity and hypertension have no greater insulin resistance than those with obesity alone, suggesting that hypertension is not generally associated with any significant increase in insulin resistance. Treatment with diltiazem or quinapril does not have undesirable effects on glucose metabolism. However, treatment with diltiazem led to a significant increase in β-cell sensitivity to glucose; this is of particular interest, given the importance of Φ1 for peripheral glucose uptake.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the Fundación Universidade-Empresa de Galicia, Warner-Lambert/Parke-Davis, Pharmaceutical Division, and in part by the Fondo de Investigaciones Sanitarias de la Seguridad Social (88/1775 and 89/0477).

PII: S0026-0495(97)90298-5

Metabolism - Clinical and Experimental
Volume 46, Issue 2 , Pages 173-178, February 1997